

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 November 2002 (21.11.2002)

PCT

(10) International Publication Number  
WO 02/092072 A3

- (51) International Patent Classification<sup>7</sup>: A61K 31/215, 31/24, 31/404, 31/44, A61P 25/28
- (21) International Application Number: PCT/EP02/05165
- (22) International Filing Date: 10 May 2002 (10.05.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
MI2001A000985 15 May 2001 (15.05.2001) IT
- (71) Applicant (for all designated States except US): NICOX S.A. [FR/FR]; 2455, routes des Dolines, Espace Gaia II - Bâtiment I, F-06906 Sophia Antipolis Cedex (FR).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): DEL SOLDATO, Piero [IT/IT]; Via Toti, 22, I-20052 Monza (IT).
- (74) Agents: SAMA, Daniele et al.; Sama Patents, Via G.B. Morgagni, 2, I-20129 Milano (IT).
- (81) Designated States (national): AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
1 May 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/092072 A3

(54) Title: DRUGS FOR THE TREATMENT OF THE ALZHEIMER DISEASE

(57) Abstract: Use for the treatment of the Alzheimer disease of compounds or salts thereof, having the following general formula (I):  $A-(B)_{x0}-(C)_{y0}-NO_2$ , wherein A contains the radical of a drug having an antiinflammatory activity, B is a bivalent linking group the precursor thereof must satisfy the tests described in the application, C is a linking group as defined in the invention.

## INTERNATIONAL SEARCH REPORT

In International Application No.

PCT/EP 02/05165

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/215 A61K31/24 A61K31/404 A61K31/44 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WENK G L ET AL: "MECHANISMS TO PREVENT THE TOXICITY OF CHRONIC NEUROINFLAMMATION ON FOREBRAIN CHOLINERGIC NEURONS" EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 402, no. 1/2, 18 August 2000 (2000-08-18), pages 77-85, XP000964665 ISSN: 0014-2999 page 78, column 1, line 4-49 page 82, column 2, line 24-36</p> <p style="text-align: center;">--- -/-</p>	1-11



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

22 November 2002

Date of mailing of the international search report

03/12/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Tardi, C

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/05165

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HAUSS-WĘGRZYŃIAK ET AL.: "The effects of a novel NSAID on chronic neuroinflammation are age dependent" NEUROBIOLOGY OF AGING, vol. 20, 1999, pages 305-313, XP002220976 abstract page 306, column 1, line 1-16 - line 37-56	1-11
Y	WO 94 12463 A (HCT HEALTH CARE TRADING LTD ;ARENA BARBARA (IT)) 9 June 1994 (1994-06-09) page 5, line 6-11; example XII; table 1	1-11
Y	WO 00 61537 A (NICOX SA ;DEL SOLDATO PIERO (IT)) 19 October 2000 (2000-10-19) page 4, line 6-10 page 7, line 11-18 page 37, line 2-8; examples 1-6	1-11
Y	US 5 192 753 A (MCGEER PATRICK L ET AL) 9 March 1993 (1993-03-09) claims 1-4	1-11
A	US 5 597 847 A (MATJI JOSE A ET AL) 28 January 1997 (1997-01-28) column 2, line 31-40	
A	MIZOGUCHI H ET AL: "LACK OF SMALL INTESTINAL ULCEROGENECITY OF NITRIC OXIDE-RELEASING INDOMETHACIN, NCX-530, IN RATS" ALIMENTARY PHARMACOLOGY & THERAPEUTICS, BLACKWELL SCIENTIFIC PUBLICATIONS LTD., CAMBRIDGE, GB, vol. 15, no. 2, 2001, pages 257-267, XP001098831 ISSN: 0269-2813 abstract page 1, column 1, paragraph 1 -page 2, column 1, line 5	
A	WALLACE J L ET AL: "NOVEL NONSTERODIAL ANTI-INFLAMMATORY DRUG DERIVATIVES WITH MARKEDLY REDUCED ULCEROGENIC PROPERTIES IN THE RAT" GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA., US, vol. 107, no. 1, 1 July 1994 (1994-07-01), pages 173-179, XP000566051 ISSN: 0016-5085 abstract	

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 02/05165

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Continuation of Box I.2

1) Present claims 1-8 and 10-11 relate to an extremely large number of possible compounds. In fact, the claims contain so many options, variables, possible permutations and provisos that a lack of clarity (and conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear and concise, namely for the compounds disclosed in claim 9.

2) Moreover, present claims 1-8 and 10-11 relate to compounds defined by reference to a desirable characteristic or property, namely they have to satisfy test 4 as described in claim 1.

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds disclosed in claim 9.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

 Int. Application No  
 PCT/EP 02/05165

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9412463	A	09-06-1994	IT 1256450 B	05-12-1995
			AT 152092 T	15-05-1997
			AU 676527 B2	13-03-1997
			AU 5624194 A	22-06-1994
			BR 9307530 A	25-05-1999
			CA 2150229 A1	09-06-1994
			DE 69310204 D1	28-05-1997
			DE 69310204 T2	20-11-1997
			DK 670825 T3	13-10-1997
			WO 9412463 A1	09-06-1994
			EP 0670825 A1	13-09-1995
			ES 2103563 T3	16-09-1997
			GR 3024018 T3	31-10-1997
			HU 73773 A2	30-09-1996
			JP 8504191 T	07-05-1996
			JP 3231043 B2	19-11-2001
			RU 2127723 C1	20-03-1999
			US 5621000 A	15-04-1997
WO 0061537	A	19-10-2000	IT MI990753 A1	13-10-2000
			AU 4400100 A	14-11-2000
			BR 0009702 A	08-01-2002
			CN 1354740 T	19-06-2002
			WO 0061537 A2	19-10-2000
			EP 1169294 A2	09-01-2002
			NO 20014927 A	13-12-2001
US 5192753	A	09-03-1993	WO 9324115 A1	09-12-1993
			EP 0642336 A1	15-03-1995
US 5597847	A	28-01-1997	IT 1256345 B	01-12-1995
			DE 69305322 D1	14-11-1996
			DE 69305322 T2	20-02-1997
			EP 0609415 A1	10-08-1994
			GR 3021404 T3	31-01-1997
			HK 1006967 A1	26-03-1999
			JP 3231042 B2	19-11-2001
			JP 7500355 T	12-01-1995
			KR 269727 B1	16-10-2000
			RU 2109009 C1	20-04-1998
			AT 143941 T	15-10-1996
			CA 2120942 A1	03-03-1994
			DK 609415 T3	18-11-1996
			WO 9404484 A1	03-03-1994
			ES 2093979 T3	01-01-1997

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 November 2002 (21.11.2002)

PCT

(10) International Publication Number  
**WO 02/092072 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 31/215**,  
31/24, 31/404, 31/44, A61P 25/28

(21) International Application Number: PCT/EP02/05165

(22) International Filing Date: 10 May 2002 (10.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
MI2001A000985 15 May 2001 (15.05.2001) IT

(71) Applicant (for all designated States except US): NICOX  
S.A. [FR/FR]; 2455, routes des Dolines, Espace Gaia II -  
Bâtiment I, F-06906 Sophia Antipolis Cedex (FR).

(72) Inventor; and

(75) Inventor/Applicant (for US only): DEL SOLDATO,  
Piero [IT/IT]; Via Toti, 22, I-20052 Monza (IT).

(74) Agents: SAMA, Daniele et al.; Sama Patents, Via G.B.  
Morgagni, 2, I-20129 Milano (IT).

(81) Designated States (national): AE, AG, AL, AU, BA, BB,  
BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE,  
HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV,  
MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK,  
TR, TT, UA, US, UZ, VN, YU, ZA.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

**Published:**

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: DRUGS FOR THE ALZHEIMER DISEASE

(57) Abstract: Use for the treatment of the Alzheimer disease of compounds or salts thereof, having the following general formula  
(I): A-(B)<sub>20</sub>-(C)<sub>20</sub>-NO<sub>2</sub>, wherein A contains the radical of a drug having an antiinflammatory activity, B is a bivalent linking group  
the precursor thereof must satisfy the tests described in the application, C is a linking group as defined in the invention.

WO 02/092072 A2



## DRUGS FOR THE ALZHEIMER DISEASE

\* \* \* \* \*

The present invention relates to the use of a particular class of drug nitrooxyderivatives in the prophylaxis and therapy of the Alzheimer disease.

The Alzheimer is a disease which mainly affects old people. The progressive ageing of people determines a significant increase of the incidence of said disease: at present in the industrialized countries the people affected by the Alzheimer disease are about 13.5 millions.

The initial symptoms of the Alzheimer dementia include a decrease of the cognitive faculties. The main characteristics of the disease comprise the following:

- amyloid deposits (amyloid plaques) in the brain parenchyma and in the vessel wall, the main component of said plaques is the  $\beta$ -amyloid protein (A $\beta$ );
- inflammatory process characterized by the activation of the microglia and by the presence of reactive astrocytes in the peri-plaque area with production of pro-inflammatory mediators, such as cytokines, NO.

Recently it has been observed that non steroidal inflammatory drugs (NSAIDs) can be useful in the disease prophylaxis and therapy (Stewart WF, Neurology 48, 626-632, 1997). These compounds have a good antiinflammatory activity at brain level, however they have the drawback not to have a high inhibition of the amyloid plaque deposition. Therefore these compounds have a limited efficacy in preventing or in the treatment of the Alzheimer disease.


Another therapeutic approach for the prevention and the treatment of the Alzheimer disease is the administration of



beta-amyloid vaccines (Schenk D. et Al. Nature 400 (6740) 173-7, 1999) or antibodies against amyloid  $\beta$ -peptide (A $\beta$ ) (F. Bard et Al. Nature vol. 6, 8, 916-919 2000). The vaccine action mechanism seems to be due to the antibody reaction versus the beta-amyloid protein. The vaccine activity in the prevention, reduction and in the treatment of the amyloid plaque deposit is higher with respect to the antiinflammatory drugs. However vaccines show the drawback to have a high immunotoxicity due to the antibody hyperproduction (Schenk, see above).

The need was felt to have available more effective compounds in the prevention, reduction and in the treatment of the deposit of the amyloid plaque with respect to the drugs of the prior art.

An object of the present invention is the use in the prophylaxis and treatment of the Alzheimer disease of compounds or salts thereof having the following general formula:




wherein:

c<sub>0</sub> is an integer and is 0 or 1, preferably 1;

b<sub>0</sub> is an integer and is 0 or 1, with the proviso that c<sub>0</sub> and b<sub>0</sub> cannot be contemporaneously equal to zero.

A = R-T<sub>1</sub>-, wherein


R is the drug radical as defined below:



(IV)

wherein:


G is one of the following groups:  $-\text{CH}=\text{CH}-$



(Vg)

M is one carbon or nitrogen atom;

P is the following group:



(V)

wherein:


the carbon atom of formula (V) is in position 5 of the ring of formula (IV);

Q is  $-\text{CH}-$  or one oxygen atom;

$q_A, q_1, q_2, q_3, q_4$ , are integers and independently the one from the other are 1 or 0;  $q_2 = q_3 = q_4 = 0$  when the ring in formula (IV) is aromatic and  $Q = -\text{CH}-$ ;  $q_2 = q_3 = q_4 = 1$  when the ring of formula (IV) is a saturated ring with 6 atoms wherein the heteroatom is  $Q = \text{O}$ , and is in position 6 of the ring;

when  $q_A = 1$  and G is the group of formula (Vg)  $R_a$  and  $R_b$ , equal or different, are hydrogen,  $C_1$ - $C_3$  alkyl, preferably methyl;


$R_c$  is hydrogen,  $C_1$ - $C_3$  alkyl, or the following radical:



(VI)


wherein  $R_M$ ,  $R_O$ ,  $R_P$ , equal or different, can be H, halogen preferably chlorine,  $C_1$ - $C_3$  alkyl, preferably methyl,  $CF_3$ ;

$R_g$  is hydrogen or  $OCH_3$  when the ring of fig. (IV) contains 6 atoms; or it is an electronic doublet when the ring with 6 atoms is aromatic and M = nitrogen; or it is a p.chlorobenzoyl radical when  $q_1 = 0$  and M = nitrogen and the ring of fig. (IV) is aromatic; or  $R_c$  and  $R_g$  taken together are such to form the following radical:



(VII)

$R_d$  in formula (IV) is hydrogen, hydroxyl,  $C_1$ - $C_4$  alkyl, optionally branched, phenyl, or the following radical:




(VIII)


$R_{a1}$  = hydrogen when  $q_2 = 1$ ;

$R_e$  = hydrogen, halogen preferably F, or benzoyl; or

$R_d$  and  $R_e$  taken together are such to form the following radicals:



(IX)



(X)

$R_{e1}$  = H when  $q_3 = 1$ ;

$R_N$  =  $C_1$ - $C_3$  alkyl preferably ethyl when  $q_4 = 1$ ;

$T_1$  =  $(CO)_t$  or  $(X)_{t'}$ , wherein  $X = O, S, NR_{1c}$ ,  $R_{1c}$  is H or a linear or branched alkyl, having from 1 to 5 carbon atoms,  $t$  and  $t'$  are integers and equal to zero or 1, with the proviso that  $t = 1$  when  $t' = 0$ ;  $t = 0$  when  $t' = 1$ ;

$B = -T_B-X_2-T_{BI}-$  wherein

$T_B$  and  $T_{BI}$  are equal or different;

$T_B = (CO)$  when the reactive function in the precursor drug is  $-OH$  or  $-NH_2$ ;  $T_B = X$ , as above, when the reactive function in the precursor drug is  $-COOH$ ;

$T_{BI} = (CO)_{tx}$  or  $(X)_{txx}$ , wherein  $tx$  and  $txx$  have the value of 0 or 1; with the proviso that  $tx = 1$  when  $txx = 0$ ,  $tx = 0$  when  $txx = 1$ ;  $X$  is as above defined;

$X_2$  is a bivalent linking group as below defined;

$C$  is the bivalent radical  $-T_c-Y-$  wherein:


when  $b0 = c0 = 1$ :  $T_c = (CO)$  when  $tx = 0$ ,  $T_c = X$  when  $txx = 0$ ,  $X$  being as above defined,

when  $b0 = 0$ :  $T_c = (CO)$  when  $t = 0$ ,  $T_c = X$  when  $t' = 0$ ,  $X$  being as above defined,

when  $c0 = 0$ :  $tx = 0$ ,  $T_{BI} = X = -O-$ ;

$Y$  has one of the following meanings:

$Y_p$ :



(III)

wherein:

$nIX$  is an integer from 0 to 3, preferably 1;

$nIIX$  is an integer from 1 to 3 preferably 1;

$R_{TIX}$ ,  $R_{TIX'}$ ,  $R_{TIIX}$ ,  $R_{TIIX'}$ , equal to or different from each other are H or linear or branched  $C_1$ - $C_4$  alkyl; preferably

$R_{TIX}$ ,  $R_{TIX'}$ ,  $R_{TIIX}$ ,  $R_{TIIX'}$  are H;


$Y^3$  is a heterocyclic ring containing one or two nitrogen atoms, said heterocyclic ring being a saturated, unsaturated or aromatic ring, having 5 or 6 atoms;

or  $Y$  can be:


$Y_0$ , selected from the following:

- an alkyleneoxy group  $R'O$  wherein  $R'$  is a linear or branched when possible  $C_1$ - $C_{20}$ , preferably having from 2 to 6 carbon atoms, or a cycloalkylene having from 5 to 7 carbon atoms, in the cycloalkylene ring one or more carbon atoms can be substituted with heteroatoms, the ring can have side chains of  $R'$  type,  $R'$  being as above;

or one of the following groups:




wherein  $nf'$  is an integer from 1 to 6 preferably from 1 to 3;




wherein  $R_{1f} = \text{H, CH}_3$  and  $nf$  is an integer from 1 to 6; preferably from 2 to 4;

or  $Y$  is  $Y_{Ar}$  and is selected from the following:



wherein  $n3$  is an integer from 0 to 3 and  $n3'$  is an integer from 1 to 3;



wherein  $n3$  and  $n3'$  have the above meaning;

with the proviso that in formula (I) when  $b0 = 0$  and the bivalent radical  $Y$  of  $C$  is  $R'O$ , the radical  $R$  of formula (IV) of the drug is ferulic acid or flurbiprofen;

-  $X_2$ , bivalent radical, is such that the corresponding precursor of  $B-T_B-X_2-T_{Bf}$  wherein the free valences of  $T_B$  and  $T_{Bf}$  are each saturated with  $OZ$ , with  $Z$  or with  $-N(Z^I)(Z^{If})$ , being:

- $Z = H, C_1-C_{10}$ , preferably  $C_1-C_5$  alkyl linear or branched when possible,
- $Z^I, Z^{II}$  equal or different have the  $Z$  values as above, depending on that  $T_B$  and/or  $T_{Br} = CO$  or  $X$ , in function of the values of  $t, t', tx$  and  $txx$ ;

it satisfies the following test (test 4): analytical determination carried out by adding aliquots of methanolic solutions at  $10^{-4}$  M concentration of the precursor of B to a methanolic solution of DPPH (2,2-diphenyl-1-picryl hydrazyl); after having maintained the solution at room temperature and sheltered from light for 30 minutes, the absorbance of the test solution and of a solution containing only DPPH in the same amount is read, at the wave length of 517 nm; then the inhibition percentage of the precursor of B towards the radical production induced by DPPH is determined by means of the formula:

$$(1 - A_s/A_c) \times 100$$

wherein  $A_s$  and  $A_c$  are respectively the absorbance values of the solution containing the test compound and DPPH and that of the solution containing only DPPH.

The acceptance criterion of the precursor compounds of B according to this test is the following: test 4 is satisfied by the precursor compounds of B when the inhibition percentage as above defined is higher than or equal to 50%.

When in formula (IV)  $q_a = 1$  and  $G$  is the group of formula (Vg) wherein  $R_a$  is methyl and  $R_b$  is hydrogen,  $q_2 = q_4 = 0$ ,  $M = C$ , and in formula (V)  $q_1 = 1$ ,  $Q = -CH-$  and  $q_3 = 0$ , the ring of formula (IV) comprising  $M$  and  $Q$  is an aromatic ring having 6 carbon atoms and the other substituents are as defined hereinafter:

- when  $R_c = R_g = R_e = H$  and  $R_d$  is isobutyl, the so defined precursor drug of R is ibuprofen;
- when  $R_c = R_g = H$  and  $R_d$  is phenyl and  $R_e$  is F, the so defined precursor drug of R is flurbiprofen;
- when  $R_c = R_g = H$  and  $R_d$  and  $R_e$  form together the radical of formula (IX), the so defined precursor drug of R is naproxen;
- when  $R_c = R_g = R_e = H$  and  $R_d$  is the radical of formula (VIII), the so defined precursor drug of R is loxoprofen;
- when  $R_c = R_g = R_d = H$  and  $R_e = \text{benzoyl}$ , the so defined precursor drug of R is ketoprofen;
- when  $R_c = R_g = H$  and  $R_d$  and  $R_e$  form together the radical of formula (X), the so defined precursor drug of R is carprofen;

when in formula (IV)  $q_1 = 0$ ,  $q_2 = q_4 = 0$ ,  $R_d = R_g = H$ ,  $M = C$ , and in formula (V)  $q_1 = 1$ ,  $Q = -CH-$ ,  $q_3 = 0$ ,  $R_e = H$ , the ring of formula (IV) comprising M and Q is an aromatic ring having 6 carbon atoms and the other substituents are defined as hereinafter:

- when  $R_c$  is the radical of formula (VI) wherein  $R_M = R_P = H$ ,  $R_O = CF_3$  and is in meta position with respect to the group  $-NH-$ , the so defined precursor drug of R is the flufenamic acid;
- when  $R_c$  is the radical of formula (VI) wherein  $R_M = R_P = Cl$  and are in the two ortho positions with respect to the  $-NH-$  group,  $R_O = CH_3$  and is in para position with respect to the  $-NH-$  group, the so defined precursor drug of R is the meclofenamic acid;
- when  $R_c$  is the radical of formula (VI) wherein  $R_M = H$ ,  $R_P = Cl$  and is in meta position with respect to the  $-NH-$



group,  $R_o = CH_3$  in orto position with respect to the -NH- group and to the chlorine atom, the so defined precursor drug of R is the tolfenamic acid;

when in formula (IV)  $q_A = 0$ ,  $M = N$ ;  $q_2 = q_4 = 0$ ,  $R_d = H$ ; and in formula (V)  $q_1 = 1$ ,  $q_3 = 0$ ,  $R_e = H$ ,  $Q = -CH-$ ;  $R_g$  is the free electronic doublet on the nitrogen atom, the ring of formula (IV) comprising M and Q is a pyridine ring,  $R_c$  is the radical of formula (VI) wherein  $R_M = R_P = H$ ,  $R_o = CF_3$  and is in meta position with respect to the -NH- group, the so defined precursor drug of R is the niflumic acid;


when in formula (IV)  $q_A = 1$  and G is the group of formula (Vg) wherein  $R_a = R_b = H$ ;  $M = C$ ,  $R_d = R_g = H$ ,  $q_2 = q_4 = 0$ ; and in formula (V)  $q_1 = 1$ ,  $Q = -CH-$ ,  $R_e = H$ ,  $q_3 = 0$ ; the ring of formula (IV) comprising M and Q is an aroamtic ring having 6 carbon atoms;  $R_c$  is the radical of formula (VI) wherein  $R_M = R_P = Cl$  and are in the two ortho positions with respect to the -NH- group,  $R_o = H$ ; the so defined precursor drug of R is diclofenac;

when in formula (IV)  $q_A = 1$  and G is the group of formula (Vg) wherein  $R_a = R_b = H$ ;  $M = C$ ,  $q_2 = q_4 = 1$ ,  $R_d = R_{d1} = H$ ,  $R_N = \text{ethyl}$ , and in formula (V)  $q_1 = 1$ ,  $q_3 = 1$ ,  $Q = O$ ,  $R_e = R_{e1} = H$ ; the ring of formula (IV) comprising M and Q is a saturated ring having 6 atoms;  $R_g$  and  $R_c$  together form the radical of formula (VII), the so defined precursor drug of radical R is etodolac;

when in formula (IV)  $q_A = 1$  and G is the group of formula (Vg) wherein  $R_a = R_b = H$ ;  $M = N$   $q_2 = q_4 = 0$ ; and in formula (V)  $q_3 = q_1 = 0$ , the ring in formula (IV) comprising M corresponds to that of pyrrole;  $R_g = \text{p.chlorobenzoyl}$ ;  $R_c = CH_3$ ;  $R_d$  together with  $R_e$  of formula (V) form the radical of

formula (IX), the so defined precursor drug of radical R is indomethacin;

when in formula (IV)  $q_A = 1$  and  $G = -HC=CH-$ ,  $q_2 = q_4 = 0$ ,  $M = C$ , and in formula (V)  $q_1 = 1$ ,  $Q = -CH-$ ,  $q_3 = 0$  and  $R_e = H$ , the ring of formula (IV) comprising M and Q is an aromatic ring having 6 carbon atoms;  $R_c = H$ ,  $R_g = OCH_3$ ,  $R_d = OH$ , the so defined precursor drug of radical R is the ferulic acid of formula (IVA)



(IVA)

The precursor compound of B which satisfies test 4 is preferably selected from the following classes of compounds:

- aminoacids, selected from the following: L-carnosine, anserine, selenocysteine, selenomethionine, penicillamine, N-acetylpenicillamine, cysteine, N-acetylcysteine, glutathione or esters thereof, preferably ethyl or isopropyl ester;
- hydroxyacids, selected from the following: gallic acid, ferulic acid, gentisic acid, citric acid, caffeic, dihydrocaffeic acid, p-cumaric acid, vanillic acid;
- aromatic and heterocyclic polyalcohols, selected from the following: nordihydroguaiaretic acid, quercetin, catechin, kaempferol, sulfuretine, ascorbic acid, isoascorbic acid, hydroquinone, gossypol, reductic acid, methoxyhydroquinone, hydroxyhydroquinone, propyl gallate, saccharose, 3,5-di-tertbutyl-4-hydroxybenzylthio glycolate, p-cumaric alcohol, 4-hydroxy-phenyl-ethylalcohol, coniferyl alcohol, allopurinol;

- compounds containing at least one free acid function, selected from the following: 3,3'-thiodipropionic acid, fumaric acid, dihydroxymaleic acid, edetic acid.

The precursor compounds of B of the above mentioned groups are prepared according to methods known in the prior art and described, for example, in "The Merck Index", 12a Ed. (1996), herein incorporated by reference.


Test 4 is a colorimetric test which allows to establish whether the precursors of B are able to inhibit the production of radicals from DPPH (2,2-diphenyl-1-picrylhydrazyl) (M.S. Nenseter et Al., Atheroscler. Thromb. 15, 1338-1344, 1995). 100  $\mu$ M solutions in methanol of the tested substances are prepared, and an aliquot of each of said solutions is added to a 0,1 M DPPH solution in methanol. After having stored the solutions at room temperature and sheltered from light for 30 minutes, the absorbance is read at the wave length of 517 nm. The absorbance decrease with respect to that of the solution containing the same DPPH concentration is determined. The effectiveness of the tested compound in inhibiting the production of radicals is expressed by the following formula:

$$(1 - A_s/A_c) \times 100$$

wherein  $A_s$  and  $A_c$  are respectively the absorbance values of the solution containing the tested compound together with DPPH and of the solution containing only DPPH.

The precursor of B satisfies test 4 if its effectiveness in inhibiting the radical production, as above defined, is equal to or higher than 50% at the indicated concentration ( $10^{-4}$  M).

Preferably  $Y^3$  is selected from the following:



Preferably  $Y^3$  is an aromatic ring having 6 atoms, containing one nitrogen atom, said aromatic ring having the two free valences in position 2 and 6.


The preferred of  $Y^3$  is Y12 (pyridyl) substituted in position 2 and 6. The bonds can also be in asymmetric position. For example Y12 (pyridyl) can be substituted also in position 2 and 3; Y1 (pyrazol) can be 3,5-disubstituted.

The precursors of Y as defined by formula (III) wherein the free valence of the oxygen is saturated with H and the free valence of the end carbon is saturated either with a carboxylic or hydroxylic group, are products available on the market or can be obtained by methods known in the prior art.


In formula (I) the preferred precursors of B for the synthesis of the nitrooxyderivatives usable in the present invention are the following: ferulic acid, N,acetylcysteine, cysteine, caffeic acid, hydrocaffeic and gentisic acid; the preferred precursor drugs of R are the following: ibuprofen, flurbiprofen, naproxen, ferulic acid of formula (IVA).

The preferred compounds of formula (I) for the use according to the present invention are the following:


- [1,1'-biphenyl]-4-acetic acid-, 2-fluoro-alpha-methyl-, 2-methoxy-4-[(1E)-3-[4-(nitrooxy)butoxy]-3-oxo-1-propenyl]phenylester (XII);
- alpha-methyl-4-(2-methylpropyl)benzenacetic acid-, 2-methoxy-4-[(1E)-3-[4-(nitrooxy)butoxy]-3-oxo-1-propenyl]phenylester (XIII);
- 6-methoxy-alpha-methyl-2-naphthalenacetic acid-, 2-methoxy-4-[(1E)-3-[4-(nitrooxy)butoxy]-3-oxo-1-propenyl]phenylester (XIV);
- (S)-N-acetylcysteine-4-(nitrooxy)butylester-, (S)-6-methoxy-alpha-methyl-2-naphthalenacetate (XV);
- (S)-N-acetylcysteine-4-(nitrooxy)butylester-, 2-fluoro-alpha-methyl-[1,1-biphenyl]-4-acetate (XVI);
- (S)-N-acetylcysteine-4-(nitrooxy)butylester-, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-acetate (XVII);
- (S)-N-acetylcysteine-4-(nitrooxy)butylester-, alpha-methyl-4-(2-methylpropyl)benzeneacetate (XVIII);
- 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid-, 2-methoxy-4-[(1E)-3-[4-(nitrooxy)butoxy]-3-oxo-1-propenyl]phenylester (XIX);
- (S)-N-acetylcysteine-4-(nitrooxy)butylester-, 2-[(2,6-dichlorophenyl)amino]benzeneacetate (XX);




(XII)




(XIII)




(XIV)




(XV)




(XVI)




(XVII)



(XVIII)



(XIX)




(XX)

Other preferred compounds of the invention are those wherein in formula (I) the precursor drug of R has formula


(IVA),  $b_0 = 0$  and  $c_0 = 1$  and C is  $Y_0$  or  $Y_{Ar}$  or  $Y_p$ , in particular the following compounds can be mentioned:

- trans 3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid-, 4-(nitrooxy)butyl ester (XXI)




(XXI)

- trans 3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid-, 3-(nitrooxymethyl)phenyl ester (XXII)



(XXII)

- trans 3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid-, 6-(nitrooxymethyl)-2-pyridinylmethylester hydrochloride (XXIII)




(XXIII)

When the precursor drug is flurbiprofen and  $b_0 = 0$ ,  $c_0 = 1$ , Y of C is  $R'O$ , the following compound can be mentioned:

2-fluoro- $\alpha$ -methyl-[1,1'-biphenyl]-4-acetic acid (nitrooxy butyl)ester (XXX):






(XXX)

Other preferred compounds of the invention are those wherein in formula (I) the precursor drug of R has formula (IVA),  $b_0 = 1$  and  $c_0 = 1$  and C is  $Y_0$  or  $Y_{Ar}$ , in particular the following compounds can be mentioned:


- (S)-N-acetylcysteine-4-(nitrooxy)butylester-, trans-3-(4-hydroxy-3-methoxyphenyl)-2-propenoate (XXIV)



(XXIV)

The preferred compound is the following:

- trans-3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid-, 2-methoxy-4-[(1E)-3-[4-(nitrooxy)butoxy]-3-oxo-1-propenyl]phenylester (XXV)



(XXV)

The nitrooxyderivatives of the compound of formula (IVA) are novel.


These compounds can be prepared by using for example the

following synthesis schemes.

The reactions are carried out by well known methods of the prior art, which allow to obtain bonds among the precursor drug, the precursor compound of B and the bivalent radical C as above defined.

1a. When the drug has the general formula R-COOH, the functional group of the precursor compound of B which binds itself to the carboxylic function of the drug has formula XZ, X being as above defined and Z = H, the reactions which take place depend on the nature of the second reactive group present in the precursor compound of B.

1a.1 When the second reactive group present in the precursor compound of B is a carboxylic group, the general synthesis scheme expects the initial formation of the acid halide R-COHal (Hal = Cl, Br) and the subsequent reaction with the HX group of the precursor compound of B:



X<sub>2</sub>, T<sub>1</sub>, T<sub>2</sub> being as above defined.

When in the two compounds under reaction other functional groups COOH and/or HX are present, they must be protected before the reaction according to the methods known in the prior art; for example as described in the volume by Th. W. Greene: "Protective groups in organic synthesis", Harvard University Press, 1980.


The RCOHal acylhalide is prepared according to the methods known in the prior art, for example by thionyl or oxalyl chloride, halides of P<sup>III</sup> or P<sup>V</sup> in solvents

inert under the reaction conditions, such as for example toluene, chloroform, DMF, etc.

In particular, if the HX group of the precursor compound of B is  $\text{NH}_2$ , or OH or SH, the precursor drug of formula R-COOH is first converted into the corresponding acyl halide RCOHal, as above mentioned, and then reacted with the HX group of the precursor compound of B in the presence of an organic base, such as triethylamine, pyridine, etc. using a solvent inert under the reaction conditions as toluene, tetrahydrofuran, etc. at a temperature in the range  $0^\circ\text{C}$ - $25^\circ\text{C}$ .

Alternatively to the previous synthesis, the precursor drug of formula R-COOH can be treated with an agent activating the carboxyl group selected from N,N'-carbonyldiimidazol (CDI), N-hydroxybenzotriazol and dicyclohexylcarbodiimide in solvent such as for example DMF, THF, chloroform etc. at a temperature in the range from  $-5^\circ\text{C}$  to  $50^\circ\text{C}$  and the obtained compound reacted in situ with the reactive function of the precursor compound of B to obtain the compound of formula (IA.1).



1a.2 When the precursor compound of B contains two functional groups XZ, equal to or different from each other, X being as above defined and  $\text{Z} = \text{H}$ , the precursor drug having formula R-COOH is first treated with an agent activating the carboxyl groups, as described in 1a.1, and then with the precursor compound of B, after having protected one of the two reactive groups HX, for example with an acetyl group or tert-butyloxycarbonyl, restoring the initial function at the end of the synthesis. The scheme is the following:




wherein X, T<sub>1</sub>, T<sub>B</sub>, X<sub>2</sub> are as above defined and G is a protective group of the HX function.

## 2. Synthesis of the nitrooxyderivative



2a.1 When the compound obtained at the end of the previous step 1a. has formula (IA.1), the acid can be converted into the corresponding sodic salt and then one can follow the methods known in the prior art for preparing the final compound, for example according to one of the following synthesis schemes:



wherein T<sub>1</sub>, T<sub>B</sub>, X<sub>2</sub>, T<sub>Br</sub>, T<sub>C</sub> are as above, R<sub>4</sub> is selected from Cl, Br, Y is as above defined, X<sub>1A</sub> is the radical Y without the oxygen atom, R<sub>3</sub> is Cl, Br, Iodine, OH. When R<sub>3</sub> = OH the compound of formula (1A.1b) is subjected to halogenation, for example with PBr<sub>3</sub>, PCl<sub>5</sub>, SOCl<sub>2</sub>, PPh<sub>3</sub> + I<sub>2</sub>, and then reacted with AgNO<sub>3</sub> in organic solvent such as acetonitrile, tetrahydrofuran. When R<sub>3</sub> is Cl, Br, Iodine, the compound of formula (1A.1b) is directly reacted with AgNO<sub>3</sub> as above mentioned.



C.)





wherein  $R_5 = OH$  or  $NHR_{1C}$ ,  $R_{1C}$ ,  $R_3$  and the other symbols being as above defined.


The above shown reactions are well known in the prior art. See for example EP 670825 B1, EP 722434 B1 and EP 759899 B1 in the name of the Applicant.

When  $X_{1A}$  is a linear  $C_4$  alkyl, the corresponding acid  $R-T_1-T_B-X_2-COOH$  is reacted with triphenylphosphine in the presence of a halogenating agent such as  $CBBr_4$  or  $N$ -bromosuccinimide in tetrahydrofuran obtaining the compound (1A.1c) wherein  $R_3 = Br$ .

2a.2 When the compound obtained at the end of the previous step 1a. has formula (IA.2), the corresponding nitrooxyderivative is obtained by treating a halogen-carboxylic acid of formula  $Hal-X_{1A}-COOH$ ,  $X_{1A}$  being as above, first with an agent activating the carboxyl group as described in 1A.1, and then with the compound of formula (IA.2), obtaining a halogen derivative, which is isolated and then dissolved in organic solvent (ref. paragraph 2a.1), and treated with silver nitrate. The global reaction scheme is the following:

1) CDI, 2)  $R-T_1-T_B-X_2-XH$







wherein  $T_1$ ,  $T_B$ ,  $X_2$ ,  $T_{BI}$ ,  $T_C$ ,  $Y$  are as above.

Alternatively, the halide  $Hal-X_1-COCl$  can be used, wherein  $Hal$  is preferably bromine, which is reacted with the compound of formula (IA.2).

1b. When the drug precursor has the reactive function  $HX$ , wherein  $X$  is as above defined, instead of a carboxylic group, the two functional groups present in the precursor compound of B can be the following:

1b.1 A carboxylic group, which reacts with the  $HX$  function of the drug precursor, and a group  $HX$ , the latter reactive group of the precursor compound of B being equal to or different from the functional group of the drug precursor. The formula of the precursor compound of B is of the  $H-X-X_2-COOH$  type, wherein  $X$  and  $X_2$  are as above.

The function  $H-X$  of the precursor compound of B is protected according to the known methods in the prior art and the carboxyl group is reacted, as above indicated, according to the following scheme:



At the end of the reaction the  $HX$  function of the precursor compound of B is restored.

1b.2 When the precursor compound of B contains two carboxylic groups, it is treated with an equimolar amount of an agent activating the carboxyl group under the conditions previously described in 1a.1, and then reacted with the reactive function  $HX$  of the drug precursor molecule. Possible other reactive functions of  $HX$  type present in the two compounds must be protected as previously

indicated. Lastly a compound of formula  $R-T_1-T_B-X_2-COOH$  (1B.2) is obtained.


2b. Synthesis of the nitrooxyderivative.

2b.1 To obtain the final nitrooxyderivative starting from the compound of formula  $R-T_1-T_B-X_2-X-H$  (1B.1), obtained at the end of the synthesis described in 1b.1, the compound (1B.1) is reacted with a halogenacid of formula  $Hal-X_{1A}-COOH$  which has been treated as previously described in paragraph 1a.1, or with the corresponding halogen acid chloride. The resulting compound is dissolved in organic solvent, for example acetonitrile or tetrahydrofuran, and reacted with silver nitrate.

2b.2 To obtain the final nitrooxyderivative starting from the compound of formula  $R-T_1-T_B-X_2-COOH$  (1B.2), obtained at the end of the synthesis described in 1b.2, the acid is transformed into the corresponding sodic salt, it is reacted with a compound  $R_4-X_{1A}-R_3$ , previously defined in the reaction scheme A. of paragraph 2a.1, obtaining according to the same procedure therein mentioned the final nitrooxyderivative. Alternatively, when  $X_{1A}$  is a linear  $C_4$  alkyl, the acid (1B.2) is reacted with triphenylphosphine in the presence of a halogenating agent such as  $CBr_4$  or N-bromosuccinimide in tetrahydrofuran and the resulting compound dissolved in organic solvent, for example acetonitrile, tetrahydrofuran, is reacted with silver nitrate.

2b.3 Alternatively to the synthesis procedure according to 1b.1 and 2b.1, it is possible to react in a first step the  $HX$ - function of the precursor compound of  $B\ HX-X_2-COOH$  with the acyl chloride of a halogenacid of formula

Hal-X<sub>1A</sub>-COCl, wherein Hal is preferably Br, and subsequently the carboxylic function of the so obtained compound with the drug precursor R-HX. In the third and last step the -Hal group is substituted with -ONO<sub>2</sub> according to the process described in 2b.1. The reaction scheme is the following:



In the previous scheme the nitration can be alternatively carried out on the acid compound of formula (2B.3).

When the compounds of formula (I) usable in the present invention have one or more chiral centres, they can be in racemic form or as mixtures of diastereoisomers, as single enantiomers or single diastereoisomers; if they show geometric asymmetry, the compounds in the cis or trans form can be used.

When in the molecule of the compounds of formula (I) a salifiable functional group is present, for example an aminic or heterocyclic nitrogen, it is possible to use the corresponding salts of the above mentioned compounds, obtainable by reaction in organic solvent such as for example acetonitrile, tetrahydrofuran, with an equimolar amount of the corresponding organic or inorganic acid.



Examples of usable organic acids are the following: oxalic, tartaric, maleic, succinic, citric acid.

Examples of usable inorganic acids are the following: nitric, hydrochloric, sulphuric, phosphoric acid. Nitric and hydrochloric acids are preferred.

It has been found that the nitrooxyderivatives used in the present invention are able to prevent the deposition of the amyloid plaque, with a higher efficacy than that of the products of the prior art. Their action mechanism is not clear yet since it has been found that they do not exert any inhibitory effect on the inflammatory process affecting the microglia. The invention results are still more surprising if one considers that the compounds used in the present invention are able to systemically release nitric oxide, which in the Alzheimer pathology is known as one of the pro-inflammatory mediators which are released further to the activation of the microglia. It was not predictable that the use of these compounds in the prophylaxis and therapy of the Alzheimer disease resulted effective.

Furthermore the compounds used in the present invention show very good tolerability, even after a long treatment. Due to the high efficacy and tolerability, they can be used also in very advanced pathology conditions.

The aforesaid compounds are formulated in the corresponding pharmaceutical compositions for parenteral, oral use according to the techniques well known in the art, together with the usual excipients; see for example the volume "Remington's Pharmaceutical Sciences 15a Ed.".

The amount on a molar basis of the active principle in said formulations is the same or lower than the maximum

posology indicated for the precursor drugs. Also higher doses can be used considering their very good tolerability. The daily doses of the precursor drugs can be found in the publications of the field, such as for example in "Physician's Desk reference".

Optionally, the use according to the present invention can be carried out by using the compounds of formula (I) in combination with one or more beta-amyloid based vaccines or antibodies against amyloid- $\beta$ -peptides ( $A\beta$ ).

The vaccines are prepared by known methods, for example as described in the publication of Schenk et al. (1999) "Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse" Nature 400(6740):173-7 and F. Bard, Nature vol. 6, 8, 916-919, 2000. In this case it is possible to reduce the administered vaccine amount with consequent reduction of the vaccine side effects of immunological nature as above indicated.

The following Examples illustrate the invention and are not limitative of its scope.

EXAMPLE 1

Synthesis of (S)-N-acetylcysteine-4-(nitrooxy)butylester, - (S)-6-methoxy-  $\alpha$ -methyl-2-naphthalenacetate of formula (XV)

a) Synthesis of (S)-N-acetyl-S-(6-methoxy- $\alpha$ -methyl-2-naphthalen acetyl)cysteine

To a solution of 6-methoxy- $\alpha$ -methyl-2-naphthalenacetic acid (10 g, 43.4 mmol) in chloroform (100 ml) and N,N-dimethylformamide (6 ml) 1,1'-carbonyldiimidazol (CDI) (7.04 g, 43.4 mmol) is added. After 15 minutes the obtained solution is treated with (S)-N-acetylcysteine (7.08 g, 43.4 mmol) and it is left at room temperature for 12 hours. The reaction mixture is washed with HCl 5%, then with water and lastly with brine. The organic phase is anhydriified with sodium sulphate and then evaporated at reduced pressure. The obtained residue is purified by chromatography on silica gel eluting with ethyl acetate. 11.66 g of the expected product are obtained in the form of a white solid m.p. 122°C-126°C.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 7.71-7.65 (3H, m), 7.34 (1H, dd), 7.16-7.09 (2H, m), 6.36 (1H, d), 4.67 (1H, m), 4.00 (1H, q), 3.90 (3H, s) 3.32 (2H, t), 1.84 (3H, s), 1.59 (3H, d).

b) Synthesis of (S)-N-acetyl-cysteine 4-(bromobutyl) ester-S-6-methoxy- $\alpha$ -methyl-2-naphthalenacetate

To a solution of the compound synthesized in the previous step (11.3 g, 30.1 mmol) in tetrahydrofuran (200 ml), triphenylphosphine (23.7 g, 90.3 mmol) and carbon tetrabromide (28.85 g, 90.3 mmol) are added. The reaction mixture is left under stirring for 24 hours at room temperature. The solvent is removed by evaporation at reduced pressure. The obtained

crude product is purified by chromatography on silica gel eluting with n-hexane/ethyl acetate 7/3. 4 g of the ester are obtained in the form of a white solid having m.p. 67°C-71°C.

c) Synthesis of (S)-N-acetylcysteine-4-(nitrooxy)butylester, - (S)-6-methoxy-  $\alpha$ -methyl-2-naphthalenacetate

To a solution of the the ester obtained at the end of the previous step (1 g, 1.96 mmoles) in acetonitrile (20 ml) silver nitrate (0.66 g, 3.92 mmoles) is added. The reaction mixture is heated for 7 hours under reflux sheltered from light. The formed salt is removed by filtration and the solution is evaporated at reduced pressure. The obtained residue is purified by chromatography on silica gel eluting with n-hexane/ethyl acetate 7/3. 0.47 g of the final product are obtained in the form of a white solid having m.p. 56°C-59°C.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 7.80-7.68 (3H, m), 7.37(1H, d), 7.20-7.13 (2H, m), 6.12 (1H, d) 4.40 (2H, dd), 4.26 (1H, m), 4.15-3.87 (3H, m), 3.92 (3H, s), 3.33 (2H, d), 1.86 (3H, d), 1.74-1.67 (4H, m), 1.61 (3H, d).

Elementary analysis:

Calculated	C: 56.08%	H: 5.73%	N: 5.71%	S: 6.51%
Found	C: 55.99%	H: 5.68%	N: 5.60%	S: 6.35%

EXAMPLE 2

Synthesis of (S)-N-acetylcysteine-4-(nitrooxy)butylester, - $\alpha$ -methyl-4-(2-methylpropyl)benzeneacetate having formula (XVIII) (NO ibuprofen)

a) Synthesis of (S)-N-acetyl-S-( $\alpha$ -methyl[4-(2-methylpropyl)benzene]acetyl)cysteine

To a solution of  $\alpha$ -methyl[4-(2-methylpropyl)benzene] acetic acid (10 g, 48.48 mmoles) in chloroform (100 ml) and N,N-

dimethylformamide (6 ml), 1,1'-carbonyldiimidazol (7.86 g, 48.48 mmol) is added. After 1 hour the obtained solution is treated with (S)-N-acetylcysteine (7.91 g, 48.47 mmol) and it is left at room temperature for 24 hours. The reaction mixture is washed with HCl 5%, then with water and lastly with brine. The organic phase is anhydriified with sodium sulphate and then evaporated at reduced pressure. The obtained residue is purified by chromatography on silica gel eluting with ethyl acetate. 13.3 g of the expected product are obtained in an oil form.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 10.17 (1H, s) 7.13 (2H, d) 6.54 (1H, d), 4.76 (1H, m), 3.93 (1H, q), 3.42-3.30 (2H, m), 2.49 (2H, d), 1.85-1.83 (4H, m), 1.55 (3H, d), 0.93 (6H, d).

b) Synthesis of (S)-N-acetylcysteine-4-(bromo)butylester, -alpha-methyl-4-(2-methylpropyl)benzeneacetate

To a solution of the compound synthetized in the previous step (12.8 g, 36.4 mmol) in tetrahydrofuran (100 ml) triphenylphosphine (28.65 g, 109.23 mmol) and carbon tetrabromide (36.23 g, 109.23 mmol) are added. The reaction mixture is left under stirring for 48 hours at room temperature. The solvent is removed by evaporation at reduced pressure. The obtained crude product is purified by chromatography on silica gel eluting with cyclohexane/ethyl acetate 1/1. 5.79 g of the ester are obtained in an oil form.

c) Synthesis of (S)-N-acetylcysteine-4-(nitrooxy)butylester, -alpha-methyl-4-(2-methylpropyl)benzeneacetate

To a solution of the ester obtained at the end of the previous step (5.5 g, 11.3 mmol) in acetonitrile (100 ml) silver nitrate (2.69 g, 15.8 mmol) is added. The reaction mixture is heated for 24 hours under reflux sheltered from

light. The formed salt is removed by filtration and the solution is evaporated at reduced pressure. The obtained residue is purified by chromatography on silica gel eluting with cyclohexane/ethyl acetate 7/3. 1.18 g of the expected product are obtained in an oil form.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 7.27-7.09 (4H, m), 6.19 (1H, d), 4.75 (1H, m), 4.47 (2H, t), 4.15-4.02 (2H, m), 3.86 (1H, q), 3.31 (2H, d), 2.44 (2H, d), 1.89 (3H, d), 1.86-1.76 (5H, m), 1.51 (3H, d), 0.89 (6H, d).

Elementary analysis:

Calculated	C: 56.39%	H: 6.88%	N: 6.00%	S: 6.84%
Found	C: 56.22%	H: 6.79%	N: 5.88%	S: 6.92%

### EXAMPLE 3

Synthesis of (S)-N-acetylcysteine-4-(nitrooxy)butylester, 1-(4-chloro benzoyl)-methoxy-2-methyl-1H-indol-3-acetate of formula (XVII)

#### a) Synthesis of (S)-N-acetyl-S-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-acetyl]cysteine

To a solution of 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-acetic acid (10 g, 28.00 mmol) in chloroform (100 ml) and N,N-dimethylformamide (2 ml), 1,1'-carbonyldiimidazole (4.53 g, 28.00 mmol) is added. After 1 hour the obtained solution is treated with (S)-N-acetylcysteine (4.56 g, 28.00 mmol) and it is left at room temperature for 24 hours. The reaction mixture is washed with HCl 5%, then with water and lastly with brine. The organic phase is anhydriified with sodium sulphate and then evaporated at reduced pressure. The obtained residue is purified by chromatography on silica gel eluting with ethyl acetate. 7.79 g of the expected product are obtained in the form of a yellow solid having m.p. 129°C.

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 12.90 (1H, s), 8.21 (1H, d), 7.69-7.64 (4H, m), 7.06 (1H, d), 6.96 (1H, d), 6.73 (1H, dd), 4.33 (1H, m), 4.02 (2H, s), 3.77 (3H, s), 3.33-2.96 (2H, m), 2.22 (3H, s), 1.78 (3H, s).

b) Synthesis of (S)- N-acetylcysteine-4-(bromo)butylester, 1-(4-chloro benzoyl)-methoxy-2-methyl-1H-indol-3-acetate

To a solution of the compound obtained in the previous step (3.09 g, 6.14 mmoles) in N,N dimethylformamide (50 ml), sodium ethylate (0.42 g, 6.14 mmoles) and, after 30 minutes, 1,4-dibromobutane (2.18 ml, 18.00 mmoli) dissolved in 25 ml of N, N dimethylformamide, are added. The reaction mixture is left under stirring for 20 hours at room temperature, then it is diluted with ethyl ether and washed with water. After the organic phase has been anhydriified with sodium sulphate the solvent is removed by evaporation at reduced pressure. The obtained crude product is purified by chromatography on silica gel eluting with cyclohexane/ethyl acetate 1/1. 1.7 g of the ester are obtained in the form of a yellow solid having m.p. 130°C-134°C.

c) Synthesis of (S)- N-acetylcysteine-4-(nitrooxy)butylester, 1-(4-chlorobenzoyl)-methoxy-2-methyl-1H-indole-3-acetate

To a solution of the ester obtained at the end of the previous step (1.6 g, 2.5 mmoles) in acetonitrile (30 ml) silver nitrate (0.6 g, 3.51 mmoles) is added. The reaction mixture is heated for 8 hours under reflux sheltered from light. The formed salt is removed by filtration and the solution is evaporated at reduced pressure. The obtained residue is purified by chromatography on silica gel eluting with cyclohexane/ethyl acetate 4/6. 1.2 g of the final product are obtained in an oil form.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 7.66 (2H, d), 7.48 (2H, d), 6.90 (2H, m), 6.68 (1H, m), 6.14 (1H, d), 4.77 (1H, m), 4.43 (2H, t), 4.08 (2H, m), 3.87 (2H, s), 3.83 (3H, s), 3.34 (2H, d), 2.38 (3H, s), 1.90 (3H, s), 1.78-1.70 (4H, m).

Elementary analysis:

Calculated C: 54.24% H: 4.88% N: 6.80% S: 5.17% Cl: 5.72%

Found C: 54.32% H: 4.93% N: 6.91% S: 5.13% Cl: 5.84%

#### EXAMPLE 4

Synthesis of (S)- N-acetylcysteine-4-(nitrooxy)butylester, 2-fluoro-alpha-methyl-[1,1-biphenyl]-4-acetate of formula (XVI)

The compound is synthesized according to the procedure described in Example 1. The substance appears as an oil. Yield: 26%.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 7.41-7.38 (6H, m), 7.10 (2H, m), 6.22 (1H, d), 4.78 (1H, m), 4.46 (2H, t), 4.13 (2H, t), 3.92 (1H, q), 3.36 (2H, d), 1.93 (3H, d), 1.76 (4H, d), 1.55 (3H, d).

Elementary analysis:

Calculated C: 56.91% H: 5.37% N: 5.55% S: 6.33% F: 3.75%

Found C: 56.99% H: 5.41% N: 5.66% S: 6.41% F: 3.83%

#### EXAMPLE 5

Synthesis of alpha-methyl-4-(2-methylpropyl)benzeneacetic acid, 2-methoxy-4-[(1E)-3-[4-(nitrooxy)butoxy]-3-oxo-1-propenyl]phenylester of formula (XIII)

a) Synthesis of the trans-3-[4-[α-methyl-[4-(-2-methylpropyl)benzene]acetyloxy]-3-methoxyphenyl]-2-propenoic acid

To a solution of α-methyl-[4-(2-methylpropyl)benzene]acetic acid (5.03 g, 24.4 mmol) in tetrahydrofuran (100 ml) and N,N-dimethylformamide (5 ml) 1,1-carbonyldiimidazole (4.25 g, 24.8 mmol) is added. After 1 hour the obtained solution is treated with ferulic acid (4.90 g, 25 mmol), sodium ethy-



late (89 mg) is added and the solution is left at room temperature under stirring for 12 hours. The reaction mixture is washed with HCl 5%, then with water and lastly with brine. The organic phase is anhydriified with sodium sulphate and evaporated at reduced pressure.

The obtained residue is purified by chromatography on silica gel eluting with ethyl acetate/n-hexane 7/3. 5.1 g of the expected product are obtained as a white solid having m.p. 131°C-137°C.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 7.72 (1H, d), 7.32 (2H, dd), 7.26 (1H, m), 7.16-7.07 (4H, m), 6.98 (1H, d), 6.37 (1H, d), 3.99 (1H, q), 3.73 (3H, s), 2.47 (2H, d), 1.88 (1H, m), 1.63 (3H, d), 0.92 (6H, d).

b) synthesis of benzenacetic acid, alpha-methyl-4-(2-methyl-propyl), 2-methoxy-4-[(1E)-3-[4-(bromo)butoxy]-3-oxo-1-propenyl]phenylester

To a solution of the compound synthetized in the previous step (5.33 g, 14 mmols) in N,N-dimethylformamide (130 ml) sodium ethylate (1.2 g, 16 mmols) is added, under stirring. After 1 hour to the obtained mixture 1,4-dibromobutane (10 g, 46 mmols) is added and it is let react at room temperature for 12 hours. The reaction mixture is washed with HCl 5%, then with water and lastly with brine; the organic phase is anhydriified with sodium sulphate and evaporated at reduced pressure. The obtained residue is purified by chromatography on silica gel eluting with n-hexane/ethyl acetate 8/2. 4.46 g of the expected product are obtained.

c) Synthesis of benzenacetic acid, alpha-methyl-4-(2-methyl-propyl), 2-methoxy-4-[(1E)-3-[4-(nitrooxy)butoxy]-3-oxo-1-propenyl]phenylester

To a solution of the compound synthesized in the previous step (4 g, 7.72 mmol) in acetonitrile (70 ml) silver nitrate (2.58 g, 15 mmol) is added. The reaction mixture is heated under reflux for 2 hours sheltered from light. At the end the formed salt is removed by filtration and the solution is evaporated at reduced pressure. The recovered residue is purified by chromatography on silica gel eluting with n-hexane/ethyl acetate 8/2. 2.4 g of the expected product are obtained as an oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 7.62 (1H, d), 7.32 (2H, d), 7.15 (2H, d), 7.16-7.05 (2H, m), 6.96 (1H, d), 6.35 (1H, d), 4.51 (2H, t), 4.24 (2H, t), 3.99 (1H, q), 3.74 (3H, s), 2.48 (2H, d), 1.89-1.83 (5H, m), 1.62 (3H, d), 0.92 (6H, d).

Elementary analysis:

Calculated	C: 64.91%	H: 6.66%	N: 2.82%
Found	C: 64.83%	H: 6.52%	N: 2.69%

EXAMPLE 6

Synthesis of [1,1'-biphenyl]-4-acetic acid, 2-fluoro-alpha-methyl, 2-methoxy-4-[(1E)-3-[4-(nitrooxy)butoxy]-3-oxo-1-propenyl]phenylester of formula (XII) (NO-flurbiprofen)

The compound is synthesized according to the procedure described in Example 5. The global yield of the process is 32%. The substance appears as an amorphous solid.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 7.40-7.25 (9H, m), 7.07-7.01 (2H, d), 6.98 (1H, m), 6.38 (1H, d), 4.44 (2H, t), 4.46 (2H, t), 4.21 (2H, t), 4.04 (1H, q), 3.73 (3H, s), 1.72 (4H, m), 1.65 (3H, d).

Elementary analysis:

Calculated C: 64.79% H: 5.25% N: 2.62% F: 3.53%

Found C: 64.85% H: 5.31% N: 2.74% F: 3.48%

#### EXAMPLE 7

Evaluation of the effect of ibuprofen and of NO-flurbiprofen (ex. 6) on the reduction of the amyloid deposits (amyloid plaques) (Protein A $\beta$ ) in the front cerebral cortex and on the activation of the microglia measured in the frontal cerebral cortex.

In this experiment transgenic rats (APPM-PS1M) having human genes and mutated by the protein precursor of the  $\beta$ -amyloid protein (APP, from which the A $\beta$  protein of the amyloid plaques forms by proteolysis) and by the preseniline-1 proteine(PS1) have been used. Mutations in these proteins cause the Alzheimer dementia in some families wherein the disease presents a dominant autosomic character. Rats carriers of the double-transgene APP mutated + PS-1 mutated (APPM/PS1M) represent a very good model for the study of Alzheimer dementia since they develop amyloid plaques and neuroinflammation like those found in the human pathology (Holcomb L. et Al. Nat. Med. 4:97 (1998)).

Three groups each formed by 12 transgenic rats (APPM/PS1M), 7 months old at the beginning of the experiment, received together with the daily diet, ibuprofen and, respectively, NO-flurbiprofen (ref. Ex. 6).

The administered pro die dose of each compound was 60 mg/kg for 5 months. The third group was the control group and received only the daily diet. At the end of the fifth month the animals were sacrificed by intra-peritoneal injection of pentobarbital (100 mg/kg). The brains were removed and the

two hemispheres separated. The hemispheres were first treated for 24 hours with a paraformaldehyde solution (4% by volume), then for a period of 8 hours each, with solutions at increasing concentrations of phosphate buffer of Soreson, respectively at 10%, 20% and 30%. The hemispheres have then been frozen and dissected along an horizontal plane and the sections have been maintained at 4°C in DPBS (Dulbecco phosphate buffer saline) with sodium azide.

The entity of the amyloid deposits has been evaluated on a part of the brain sections obtained by coloration with Congo Red (Sheehan DC, Hrapchak BB, eds. Theory and Practice of Histotechnology, 2<sup>nd</sup> ed. Mosby, St. Louis (MO), 1980, pp. 177-178; Thompson SW, ed. Selected Histochemical and Histopathological Methods. Charles C. Thomas, Springfield (IL), 1966, pp. 402-405), and on a further part of the brain sections by treatment with polyclonal antibody specific versus peptide A $\beta$ , in order to identify by a subsequent immunochemical method the A $\beta$  deposits.

Another part of the sections obtained from the frontal cortex has been analyzed by immunohistochemical analysis by using antibodies directed against microglial activation indicators: anti-MHC-II, directed against the histocompatibility complex of type II, anti-CR111 which recognizes the complement receptor 3. Expression of these indicators results increased in the activated microglia. The microglia presence has been quantified by videodensitometric analysis and the positive microglial cells for MHC-II have been counted in various areas of each brain section and the results have been expressed as average number of positive MHC-II cells for tissue section.

The results are reported in Tables 1 and 2.

The results reported in Table 1 show that NO-flurbiprofen induces a significant reduction of the amyloid plaque deposits (A $\beta$  deposits) in treated animals with respect to ibuprofen.

The ibuprofen activity results remarkably lower than that of the compounds according to the present invention.

The results reported in Table 2 are expressed as a ratio between the average number of activated microglial cells (positive MCH-II) counted in the cerebral sections of the three groups of animals and the average number of activated microglial cells counted in the cerebral sections of the control group. Said results show that in the group of rats treated with NO-flurbiprofen the number of the microglial cells is about 25 times higher than that of the controls and that in the group treated with ibuprofen the number of the activated cells is about 6 times higher than that of the controls.

#### EXAMPLE 8

Evaluation of the gastric damages induced by flurbiprofen and ibuprofen with respect to the corresponding nitrooxyderivatives according to the present invention

The gastric tolerability of these drugs has been evaluated in rats (groups of 10 rats each) treated for short or long period, according to conventional protocols, respectively with NO-flurbiprofen as above defined, an equimolar dose of flurbiprofen, or with ibuprofen or with an equimolar dose of NO-ibuprofen.

The administered doses and the obtained results are reported in Table 3 and show that administration of flurbipro-

fen causes gastric damages, while NO-flurbiprofen does not damage the gastric mucosa, and is more tolerated.

#### EXAMPLE 9

Efficacy of NO-flurbiprofen (ex. 6), of 4-nitrooxy butyl derivative of flurbiprofen (NO-C<sub>4</sub>-flurbiprofen), of 4-nitrooxybutyl derivative of aspirin (NO-ASA) and of flurbiprofen in inhibiting the cerebral neurodegeneration in rats treated with LPS

The nitrooxybutyl derivative of aspirin (NO-ASA) and the nitrooxybutyl derivative of flurbiprofen (NO-C<sub>4</sub>- flurbiprofen) have been synthesized according to the method reported in the patent application WO 95/30641 in the name of the Applicant.

72 male rats F-344, 3-months old, have been divided in 5 groups, which were chronically infused with LPS (lypopolysaccharide) for 30 days and received once a day for the same period of time, by subcutaneous injection respectively NO-ASA (90 mg/kg equivalent to 302  $\mu$ moles/Kg), NO-flurbiprofen (14  $\mu$ moles/kg), NO-C<sub>4</sub>-flurbiprofen (15 mg/Kg equivalent to 41.5  $\mu$ moles/kg), flurbiprofen (3 mg/Kg equivalent to 12.3  $\mu$ moles/kg), or only the same volume of solvent (controls). The solvent was formed by a mixture of dimethylsulphoxide/ethanol/castor oil 20/5/75 by volume.

At the end rats were sacrificed by lethal injection with pentobarbital.

#### Fixation procedure for cerebral tissues

The brain of each rat was perfused in situ at first with a cold saline solution containing 1 U/ml of heparin, then with paraformaldehyde 4% in phosphate buffer 0,1 M (pH 7.4). The brains have been dissected, further on fixed for 1 h in the

same solutions and incubated for one night in a cryoprotective solution containing 20% by weight of sucrose. The frozen tissues were gradually warmed up to -20°C and front serial sections were cut by a cryostat. The sections have been collected in phosphate buffer, then immediately used or otherwise maintained overnight.

The sections were washed and incubated in phosphate buffer and incubated overnight at room temperature with primary antibodies for specific epitoms. The activated microglia was visualized by using the antibody OX-6 directed against the histocompatibility complex of class II (MHC-II). Sections have been incubated for 1 h with the secondary biotinylated antibody (mouse anti-IgG, obtained in horse) and then with avidin conjugated with peroxidase (1 h). Then, the sections were treated for 1-5 min with 0.05% of a solution of 3,3'-diaminobenzidine tetrahydrochloride, which is the peroxidase substratum. The dye was removed by washings with PBS.

The brain sections were then analyzed by microscopy. The number of positive microglial cells for OX-6 in the dentate ring and in the CA1-4 areas of the hippocampus were counted in identical brain sections from each rat.

The results, expressed as inhibition percentage of the neurodegenerative process with respect to the controls, are reported in Table 4 and show that the nitrooxyderivatives NO-flurbiprofen and NO-C<sub>4</sub>-flurbiprofen according to the invention are more effective in inhibiting the neurodegenerative process induced by LPS with respect to NO-ASA. Flurbiprofen at the tested dose, that is comparable with that of NO-C<sub>4</sub>-flurbiprofen, is ineffective and caused gastric lesions in the animals. The

NO-ASA activity is on the contrary very lower than that of the two previous compounds.

Table 1

Inhibition of the amyloid plaque deposit in transgenic rats (APP+PS1) in consequence of the treatment with ibuprofen and NO-flurbiprofen, respectively. The controls have not received any pharmacological treatment		
Treatment	Inhibition % (histochemical method <sup>1</sup> )	Inhibition % (imunochemical method <sup>2</sup> )
Controls	0	0
NO- Flurbiprofen	40	45
Ibuprofen	14	27

<sup>1</sup> Coloration with congo red;

<sup>2</sup> Dosage A $\beta$  I by imunocytochemical method



Table 2

<p>Immuno-histochemical analysis of the activation of microglial cells in consequence of the treatment with ibuprofen and NO-flurbiprofen, respectively.</p> <p>The controls have not received any pharmacological treatment. The results are expressed as ratio between the average number of microglial cells in each group of rats with respect to that of the controls (<math>R_{ATT}</math>)</p>	
Treatment	$R_{ATT}$
Controls	1
NO-Flurbiprofen	25
Ibuprofen	6

Table 3


<p>Gastric toxicity of ibuprofen and flurbiprofen with respect to NO-ibuprofen and NO-flurbiprofen respectively</p>					
Compounds	Dose (mg/kg)	Gastric Damage Score	Compounds	Dose (mg/kg)	Gastric Damage Score
Ibuprofen	3	1	Flurbiprofen	1	5
	10	1		3	10
	30	3.5		10	10
	100	16.5		30	19
NO-Ibuprofen	6.8	0.5	NO-flurbiprofen	2.2	0
	22.7	0.5		6.6	0
	68	2		22	0
	227	0.5		66	0

Table 4

Comparison among the efficacy of NO-flurbiprofen, of nitrooxy-butyl derivative of aspirin (NO-ASA) and of nitrooxybutyl derivative of flurbiprofen (NO-C <sub>4</sub> -flurbiprofen) in inhibiting the cerebral neurodegeneration in rats treated with LPS.		
Treatment	Dose $\mu$ moles/Kg	Neurodegeneration inhibition %
Controls	-	0
NO-ASA	302	27.5
NO-C <sub>4</sub> -Flurbiprofen	41.5	71
NO-Flurbiprofen	14	71
Flurbiprofen	12,3	0

## CLAIMS

1. Use for the preparation of drugs in the prophylaxis and treatment of the Alzheimer disease of compounds, or salts thereof, having the following general formula:




wherein:

$c_0$  is an integer and is 0 or 1, preferably 1;

$b_0$  is an integer and is 0 or 1, with the proviso that  $c_0$  and  $b_0$  cannot be contemporaneously equal to zero.

$A = R-T_1-$ , wherein


$R$  is the drug radical as defined below:



(IV)

wherein:


$G$  is one of the following groups:  $-CH=CH-$ ,



(Vg)

$M$  is one carbon or nitrogen atom;

$P$  is the following group:



(V)

wherein:


the carbon atom of formula (V) is in position 5 of the ring of formula (IV);

Q is -CH- or one oxygen atom;

$q_A$ ,  $q_1$ ,  $q_2$ ,  $q_3$ ,  $q_4$ , are integers and independently the one from the other are 1 or 0;  $q_2 = q_3 = q_4 = 0$  when the ring in formula (IV) is aromatic and  $Q = -CH-$ ;  $q_2 = q_3 = q_4 = 1$  when the ring of formula (IV) is a saturated ring with 6 atoms wherein the heteroatom is  $Q = O$ , and is in position 6 of the ring;

when  $q_A = 1$  and G is the group of formula (Vg)  $R_a$  and  $R_b$ , equal or different, are hydrogen,  $C_1$ - $C_3$  alkyl, preferably methyl;


$R_e$  in formula (IV) is hydrogen,  $C_1$ - $C_3$  alkyl, or the following radical:



(VI)


wherein  $R_M$ ,  $R_O$ ,  $R_P$ , equal or different, can be H, halogen preferably chlorine,  $C_1$ - $C_3$  alkyl preferably methyl,  $CF_3$ ;

$R_g$  is hydrogen or  $-OCH_3$ , when the ring of fig. (IV) has 6 atoms; or it is an electronic doublet when the ring having 6 atoms is aromatic and  $M$  = nitrogen; or it is a p.chlorobenzoyl radical when  $q_1 = 0$  and  $M$  = nitrogen and the ring of fig. (IV) is aromatic; or  $R_c$  and  $R_g$  taken together are such to form the following radical:



(VII)

$R_d$  in formula (IV) is hydrogen, hydroxyl,  $C_1$ - $C_4$  alkyl, optionally branched, phenyl, or the following radical:




(VIII)


$R_{d1}$  = hydrogen when  $q_2 = 1$ ;

$R_e$  (formula V) = hydrogen, halogen preferably F, or benzoyl; or

$R_d$  and  $R_e$  taken together are such to form the following radicals:



(IX)



(X)

$R_{e1}$  (formula V) = H when  $q_3 = 1$ ;

$R_N$  (formula IV) =  $C_1$ - $C_3$  alkyl preferably ethyl when  $q_4 = 1$ ;

$T_1 = (CO)_t$  or  $(X)_{t'}$ , wherein  $X = O, S, NR_{1c}$ ,  $R_{1c}$  is H or a linear or branched alkyl, having from 1 to 5 carbon atoms,  $t$  and  $t'$  are integers and equal to zero or 1, with the proviso that  $t = 1$  when  $t' = 0$ ;  $t = 0$  when  $t' = 1$ ;

$B = -T_B-X_2-T_{BI}-$  wherein

$T_B$  and  $T_{BI}$  are equal or different;

$T_B = (CO)$  when the reactive function in the precursor drug is  $-OH$  or  $-NH_2$ ;  $T_B = X$ , as above, when the reactive function in the precursor drug is  $-COOH$ ;

$T_{BI} = (CO)_{tx}$  or  $(X)_{txx}$ , wherein  $tx$  and  $txx$  have the value of 0 or 1; with the proviso that  $tx = 1$  when  $txx = 0$ ,  $tx = 0$  when  $txx = 1$ ;  $X$  is as above defined;

$X_2$  is a bivalent linking group as defined below;

$C$  is the bivalent radical  $-T_c-Y-$  wherein


when  $b0 = c0 = 1$ :  $T_c = (CO)$  when  $tx = 0$ ,  $T_c = X$  when  $txx = 0$ ,  $X$  being as above defined,

when  $b0 = 0$ :  $T_c = (CO)$  when  $t = 0$ ,  $T_c = X$  when  $t' = 0$ ,  $X$  being as above defined,

when  $c0 = 0$ :  $tx = 0$ ,  $T_{BI} = X = -O-$ ;

$Y$  has one of the following meanings:

$Y_p$  :



wherein:

$n_{IX}$  is an integer from 0 to 3, preferably 1;

$n_{IIX}$  is an integer from 1 to 3 preferably 1;


$R_{TIX}$ ,  $R_{TIX'}$ ,  $R_{TIIIX}$ ,  $R_{TIIIX'}$ , equal to or different from each other are H or linear or branched  $C_1$ - $C_4$  alkyl; preferably  $R_{TIX}$ ,  $R_{TIX'}$ ,  $R_{TIIIX}$ ,  $R_{TIIIX'}$  are H.

$Y^3$  is a heterocyclic ring containing one or two nitrogen atoms, said heterocyclic ring being a saturated, unsaturated or aromatic ring, having 5 or 6 atoms;


or Y may be:

$Y_0$ , selected from the following:

- an alkylenoxy group  $R'O$  wherein  $R'$  is a linear or branched when possible  $C_1$ - $C_{20}$ , preferably having from 2 to 6 carbon atoms, or a cycloalkylene having from 5 to 7 carbon atoms, in the cycloalkylene ring one or more carbon atoms can be substituted with heteroatoms, the ring can have side chains of  $R'$  type,  $R'$  being as above; or one of the following groups:




wherein  $nf'$  is an integer from 1 to 6 preferably from 1 to 3;




wherein  $R_{1f} = \text{H, CH}_3$  and  $nf$  is an integer from 1 to 6; preferably from 2 to 4;

or  $Y$  is  $Y_{Ar}$  and is selected from the following:



wherein  $n3$  is an integer from 0 to 3 and  $n3'$  is an integer from 1 to 3;



wherein  $n3$  and  $n3'$  have the above meaning;

with the proviso that in formula (I) when  $b0 = 0$  and the bivalent radical  $Y$  of  $C$  is  $R'O$ , the radical  $R$  of formula (IV) of the drug is ferulic acid or flurbiprofen;

$X_2$ , bivalent radical, is such that the corresponding precursor of  $B-T_B-X_2-T_{BI}$  wherein the free valences of  $T_B$  and  $T_{BI}$  are each saturated with  $OZ$ , with  $Z$  or with  $-N(Z^I)(Z^{II})$ , being:

- $Z = \text{H, C}_1\text{-C}_{10}$ , preferably a linear or branched when possible  $\text{C}_1\text{-C}_5$  alkyl,
- $Z^I, Z^{II}$  equal or different have the values of  $Z$  as above, depending on that  $T_B$  and/or  $T_{BI} = \text{CO}$  or  $X$ , in function of the values of  $t, t', tx$  and  $txx$ ;

it satisfies the following test (test 4): analytical de-



termination carried out by adding aliquots of methanolic solutions at  $10^{-4}$  M concentration of the precursor of B to a methanolic solution of DPPH (2,2-diphenyl-1-picrylhydrazyl); after having maintained the solution at room temperature and sheltered from light for 30 minutes, the absorbance of the test solution and of a solution containing only DPPH in the same amount is read, at the wavelength of 517 nm; then the inhibition percentage of the precursor of B towards the radical production induced by DPPH is determined by means of the formula:

$$(1 - A_s/A_c) \times 100$$

wherein  $A_s$  and  $A_c$  are respectively the absorbance values of the solution containing the test compound and DPPH and that of the solution containing only DPPH.

The acceptance criterion of the precursor compounds of B according to this test is the following: test 4 is satisfied by the precursor compounds of B when the inhibition percentage as above defined is higher than or equal to 50%.

2. Use according to claim 1, wherein:

- when in formula (IV)  $q_A = 1$  and G is the group of formula (Vg) wherein  $R_A$  is methyl and  $R_B$  is hydrogen,  $q_2 = q_4 = 0$ ,  $M = C$ , and in formula (V)  $q_1 = 1$ ,  $Q = -CH-$  and  $q_3 = 0$ , the ring of formula (IV) comprising M and Q is an aromatic ring having 6 carbon atoms and the other substituents are as defined hereinafter:

- when  $R_c = R_g = R_e = H$  and  $R_d$  is isobutyl, the so defined precursor drug of R is ibuprofen;
- when  $R_c = R_g = H$  and  $R_d$  is phenyl and  $R_e$  is F, the so defined precursor drug of R is flurbiprofen;

- when  $R_c = R_g = H$  and  $R_d$  and  $R_e$  form together the radical of formula (IX), the so defined precursor drug of R is naproxen;
- when  $R_c = R_g = R_e = H$  and  $R_d$  is the radical of formula (VIII), the so defined precursor drug of R is loxoprofen;
- when  $R_c = R_g = R_d = H$  and  $R_e = \text{benzoyl}$ , the so defined precursor drug of R is ketoprofen;
- when  $R_c = R_g = H$  and  $R_d$  and  $R_e$  form together the radical of formula (X), the so defined precursor drug of R is carprofen;
- when in formula (IV)  $q_A = 0$ ,  $q_2 = q_4 = 0$ ,  $R_d = R_g = H$ ,  $M = C$ , and in formula (V)  $q_1 = 1$ ,  $Q = -CH-$ ,  $q_3 = 0$ ,  $R_e = H$ , the ring of formula (IV) comprising M and Q is an aromatic ring having 6 carbon atoms and the other substituents are as defined hereinafter:
  - when  $R_c$  is the radical of formula (VI) wherein  $R_M = R_p = H$ ,  $R_o = CF_3$  and is in meta position with respect to the  $-NH-$  group, the so defined precursor drug of R is the flufenamic acid;
  - when  $R_c$  is the radical of formula (VI) wherein  $R_M = R_p = Cl$  and are in the two ortho positions with respect to the  $-NH-$  group,  $R_o = CH_3$  and is in para position with respect to the  $-NH-$  group, the so defined precursor drug of R is the meclofenamic acid;
  - when  $R_c$  is the radical of formula (VI) wherein  $R_M = H$ ,  $R_p = Cl$  and is in meta position with respect to the  $-NH-$  group,  $R_o = CH_3$  in ortho position with respect to the  $-NH-$  group and to the chlorine atom,

the so defined precursor drug of R is the tolfenamic acid;

- when in formula (IV)  $q_A = 0$ ,  $M = N$ ;  $q_2 = q_4 = 0$ ,  $R_d = H$ ; and in formula (V)  $q_1 = 1$ ,  $q_3 = 0$ ,  $R_e = H$ ,  $Q = -CH-$ ;  $R_g$  is the free electronic doublet on the nitrogen atom, the ring of formula (IV) comprising M and Q is a pyridine ring,  $R_c$  is the radical of formula (VI) wherein  $R_M = R_P = H$ ,  $R_o = CF_3$  and is in meta position with respect to the  $-NH-$  group, the so defined precursor drug of R is the niflumic acid;


- when in formula (IV)  $q_A = 1$  and G is the group of formula (Vg) wherein  $R_a = R_b = H$ ;  $M = C$ ,  $R_d = R_g = H$ ,  $q_2 = q_4 = 0$ ; and in formula (V)  $q_1 = 1$ ,  $Q = -CH-$ ,  $R_e = H$ ,  $q_3 = 0$ ; the ring of formula (IV) comprising M and Q is an aromatic ring having 6 carbon atoms;  $R_c$  is the radical of formula (VI) wherein  $R_M = R_P = Cl$  and are in the two ortho positions with respect to the  $-NH-$  group,  $R_o = H$ ; the so defined precursor drug of R is diclofenac;

- when in formula (IV)  $q_A = 1$  and G is the group of formula (Vg) wherein  $R_a = R_b = H$ ;  $M = C$ ,  $q_2 = q_4 = 1$ ,  $R_d = R_{d1} = H$ ,  $R_N = \text{ethyl}$ , and in formula (V)  $q_1 = 1$ ,  $q_3 = 1$ ,  $Q = O$ ,  $R_e = R_{e1} = H$ ; the ring of formula (IV) comprising M and Q is a saturated ring having 6 atoms;  $R_g$  and  $R_c$  together form the radical of formula (VII), the so defined precursor drug of radical R is etodolac;

- when in formula (IV)  $q_A = 1$  and G is the group of formula (Vg) wherein  $R_a = R_b = H$ ;  $M = N$   $q_2 = q_4 = 0$ ; and in formula (V)  $q_3 = q_1 = 0$ , the ring in formula (IV) comprising M corresponds to that of pyrrol;  $R_g = p\text{-chlorobenzoyl}$ ;  $R_c = CH_3$ ;  $R_d$  together with  $R_e$  of formula

(V) form the radical of formula (IX), the so defined precursor drug of radical R is indomethacin.

3. Use according to claim 1, wherein when in formula (IV)  $q_A = 1$  and  $G = -HC=CH-$ ,  $q_2 = q_4 = 0$ ,  $M = C$ , and in formula (V)  $q_1 = 1$ ,  $Q = -CH-$ ,  $q_3 = 0$  and  $R_e = H$ , the ring of formula (IV) comprising M and Q is an aromatic ring having 6 carbon atoms;  $R_c = H$ ,  $R_g = OCH_3$ ,  $R_d = OH$ , the so defined precursor drug of radical R is the ferulic acid of formula (IVA)






(IVA)

4. Use according to claims 1-3, wherein the precursor compound of B which satisfies test 4 is selected from the following classes of compounds:
- aminoacids, selected from the following: L-carnosine, anserine, selenocysteine, selenomethionine, penicillamine, N-acetylpenicillamine, cysteine, N-acetylcysteine, glutathione or esters thereof, preferably ethyl or isopropyl ester;
  - hydroxyacids, selected from the following: gallic acid, ferulic acid, gentisic acid, citric acid, caffeic, dihydrocaffeic acid, p-cumaric acid, vanillic acid;
  - aromatic and heterocyclic polyalcohols, selected from the following: nordihydroguaiaretic acid, quercetin, catechin, kaempferol, sulphuretin, ascorbic acid, isoascorbic acid, hydroquinone, gossypol, re-

ductic acid, methoxyhydroquinone, hydroxyhydroquinone, propyl gallate, saccharose, 3,5-di-tertbutyl-4-hydroxybenzylthio glycolate, p-cumaric alcohol, 4-hydroxy-phenylethylalcohol, coniferyl alcohol, allo-purinol;

- compounds containing at least one free acid function, selected from the following: 3,3'-thiodipropionic acid, fumaric acid, dihydroxymaleic acid, edetic acid.

5. Use according to claims 1-4, wherein  $Y^3$  in formula (III) is selected from the following:



6. Use according to claim 5, wherein  $Y^3$  is an aromatic ring having 6 atoms, containing one nitrogen atom and having the two free valences respectively in position 2 and 6.
7. Use according to claims 6, wherein  $Y^3$  is Y12 (pyridyl) substituted in position 2 and 6 or having the two bonds also in asymmetric position.

8. Use according to claims 1-7, wherein the precursors of B of formula (I) for the synthesis of the nitrooxyderivatives usable in the present invention are the following: ferulic acid, N-acetylcysteine, cysteine, caffeic acid, hydrocaffeic and gentisic acid; and the precursor drugs of R are the following: ibuprofen, flurbiprofen, naproxen, ferulic acid.
9. Use according to claims 1-8, wherein the compounds of formula (I) are the following:
- [1,1'-biphenyl]-4-acetic acid-, 2-fluoro-alpha-methyl-, 2-methoxy-4-[(1E)-3-[4-(nitrooxy)butoxy]-3-oxo-1-propenyl]phenylester (XII);
  - alpha-methyl-4-(2-methylpropyl) benzenacetic acid-, 2-methoxy-4-[(1E)-3-[4-(nitrooxy)butoxy]-3-oxo-1-propenyl]phenylester (XIII);
  - 6-methoxy-alpha-methyl-2-naphthalenacetic acid-, 2-methoxy-4-[(1E)-3-[4-(nitrooxy)butoxy]-3-oxo-1-propenyl]phenylester (XIV);
  - (S)-N-acetylcysteine-4-(nitrooxy)butylester-, (S)-6-methoxy-alpha-methyl-2-naphthalenacetate (XV);
  - (S)-N-acetylcysteine-4-(nitrooxy)butylester-, 2-fluoro-alpha-methyl-[1,1-biphenyl]-4-acetate (XVI);
  - (S)-N-acetylcysteine-4-(nitrooxy)butylester-, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-acetate (XVII);
  - (S)-N-acetylcysteine-4-(nitrooxy)butylester-, alpha-methyl-4-(2-methylpropyl)benzeneacetate (XVIII);
  - 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid-, 2-methoxy-4-[(1E)-3-[4-(nitrooxy)butoxy]-3-oxo-1-propenyl]

phenylester (XIX);

- (S)-N-acetylcysteine-4-(nitrooxy)butylester-, 2-[(2,6-dichlorophenyl)amino]benzeneacetate (XX);
- trans-3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid-, 4-(nitrooxy)butyl ester (XXI);
- trans 3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid-, 3-(nitrooxymethyl)phenyl ester (XXII);
- trans 3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid-, 6-(nitrooxymethyl)-2-pyridinylmethyl ester hydrochloride (XXIII);
- 2-fluoro-alpha-methyl-[1,1'-biphenyl]-4-acetic acid (nitrooxy butyl)ester (XXX);
- (S)-N-acetylcysteine-4-(nitrooxy)butylester-, trans-3-(4-hydroxy-3-methoxyphenyl)-2-propenoate (XXIV);
- trans-3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid-, 2-methoxy-4-[(1E)-3-[4-(nitrooxy)butoxy]-3-oxo-1-propenyl]phenylester (XXV).

10. Use according to claims 1-9, wherein if the compounds of formula (I) have one or more chiral centres, they are used in racemic form or as mixtures of diastereoisomers, as single enantiomers or single diastereoisomers; if they show geometric asymmetry, the compounds in the cis or trans form are used.
11. Use according to claims 1-10, wherein the compounds of formula (I) are used in combination with one or more vaccines.
12. Mixtures of compounds as defined in claim 11.
13. Compounds according to claim 9, selected from:
  - trans 3-(4-hydroxy-3-methoxyphenyl)-2-propenoic

- acid-, 4-(nitrooxy)butyl ester (XXI);
- trans 3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid-, 3-(nitrooxymethyl)phenyl ester (XXII);
  - trans 3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid-, 6-(nitrooxymethyl)-2-pyridinylmethyl ester hydrochloride (XXIII);
  - (S)-N-acetylcysteine-4-(nitrooxy)butylester-, trans-3-(4-hydroxy-3-methoxyphenyl)-2-propenoate (XXIV);
  - trans-3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid-, 2-methoxy-4-[(1E)-3-[4-(nitrooxy)butoxy]-3-oxo-1-propenyl]phenylester (XXV).